Hexane-2,5-dione

Synonyms: 2,5-HD
Hexane-2,5-dione (2,5-HD) 是一种具有口服活性且可穿透血脑屏障的细胞毒性剂,可降低 BCL-2 及 β-连环蛋白 (β-catenin)/TCF 的转录活性、上调 BAX 及活化型 caspase-3 的表达并促进细胞凋亡 (apoptosis),还可导致大鼠轴突内神经丝聚集,可用于神经退行性疾病的研究。
产品编号: MS-T25970 纯度: 99.96% CAS No.: 110-13-4 分子式: C6H10O2 分子量: 114.14
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
50g
询价
3-5 天
100g
询价
3-5 天
500g
询价
3-5 天
1kg
询价
3-5 天

产品描述

Hexane-2,5-dione (2,5-HD) 是一种具有口服活性且可穿透血脑屏障的细胞毒性剂,可降低 BCL-2 及 β-连环蛋白 (β-catenin)/TCF 的转录活性、上调 BAX 及活化型 caspase-3 的表达并促进细胞凋亡 (apoptosis),还可导致大鼠轴突内神经丝聚集,可用于神经退行性疾病的研究。

生物实验数据

生物活性 Hexane-2,5-dione (2,5-HD) is an orally active cytotoxic agent capable of penetrating the blood-brain barrier that decreases the transcriptional activity of BCL-2 and β-catenin/TCF, upregulates the expression of BAX and activated caspase-3, promotes apoptosis, induces intra-axonal neurofilament aggregation in rats, and can be used for research on neurodegenerative diseases.
体外研究
(In Vitro)

Hexane-2,5-dione (16-256 μM; 24 h) 可诱导人原代卵巢颗粒细胞发生与凋亡一致的形态学改变。
Hexane-2,5-dione (16-256 μM; 24 h) 可诱导原代人卵巢颗粒细胞发生剂量依赖性凋亡。
Hexane-2,5-dione (64-256 μM; 24 h) 以剂量依赖的方式下调原代人卵巢颗粒细胞中 BCL-2 mRNA 的表达,并上调 BAX 和 CASPASE-3 mRNA 的表达。
Hexane-2,5-dione (64-256 μM; 24 h) 在原代人卵巢颗粒细胞中以剂量依赖的方式下调 BCL-2 蛋白,并上调 BAX 和活化型 CASPASE-3 (p17 亚基) 蛋白。
2,5-Hexanedione (100 mM; 16 h) 可修饰纯化的牛脑微管蛋白,形成一种具有增强成核活性的促组装组分,表现为组装临界浓度降低 19 倍,且 α-微管蛋白结构发生改变。
2,5-Hexanedione (2,5-HD) 可在体外交联微管,从而降低其驱动基于驱动蛋白的运输的能力。
Hexane-2,5-dione (20-60 mM; 24 h) 可诱导大鼠卵巢颗粒细胞发生 G0/G1 期细胞周期阻滞,同时伴随细胞周期相关基因 p21、Cdk2 和 Ccnd1 的表达改变。
Hexane-2,5-dione (40-60 mM; 24 h) 可改变大鼠卵巢颗粒细胞中凋亡相关蛋白的表达,下调 Bcl-2 并上调 Bax、Caspase3 及 Caspase9。
Hexane-2,5-dione (60 mM; 24 h) 可改变大鼠卵巢颗粒细胞的 mRNA 和 miRNA 表达谱,差异表达基因在细胞周期和 Wnt/β-catenin 信号通路中显著富集。
Hexane-2,5-dione (20-60 mM; 24 h) 可剂量依赖性地抑制大鼠卵巢颗粒细胞中的 Wnt/β-catenin 信号通路,降低关键受体与转录因子的 mRNA 表达水平,并改变 β-catenin、GSK3β、p-β-catenin 及 Dvl3 的蛋白表达。
Hexane-2,5-dione (20-60 mM; 24 h) 可呈剂量依赖性降低大鼠卵巢颗粒细胞中 β-catenin 的核定位。
Hexane-2,5-dione (10 mM; 6-12 h) 可降低 COV434 人卵巢颗粒细胞的细胞活力。
Hexane-2,5-dione (10-160 mM; 6-12 h) 对大鼠卵巢颗粒细胞的活力无显著影响。
Hexane-2,5-dione (10-20 mM; 6 h) 可剂量依赖性地抑制人卵巢颗粒细胞瘤 COV434 细胞中 β-catenin/TCF 的转录活性。
Hexane-2,5-dione (20-60 mM; 24 h) 可改变大鼠卵巢颗粒细胞中 Wnt 通路相关 miRNA 的表达,下调 rno-miR-214-3p、rno-miR-138-5p、rno-miR-199a-3p、rno-miR-145-5p 及 rno-miR-143-3p。

Apoptosis Analysis

Cell Line: primary human ovarian granulosa cells
Concentration: 16; 64; 256 μM
Incubation Time: 24 h
Result: Induced morphological changes consistent with apoptosis in primary human ovarian granulosa cells.
Induced dose-dependent apoptosis.
Showed total apoptotic rates reaching 7.8%, 26.8%, and 56.3%, at 16, 64, 256 μM, respectively.

Real Time qPCR

Cell Line: primary human ovarian granulosa cells
Concentration: 16; 64; 256 μM
Incubation Time: 24 h
Result: Reduced BCL-2 mRNA and increased BAX and CASPASE-3 mRNA in a dose-dependent manner.
Showed no no significant effect on these gene levels at 16 μM.

Western Blot Analysis

Cell Line: primary human ovarian granulosa cells
Concentration: 16; 64; 256 μM
Incubation Time: 24 h
Result: Downregulated BCL-2 protein and upregulated BAX and active CASPASE-3 (p17 subunit) protein in a dose-dependent manner.
Showed no no significant effect on these protein levels at 16 μM.

Cell Viability Assay

Cell Line: COV434 human ovarian granulosa cells
Concentration: 10; 20; 40; 80; 160 mM
Incubation Time: 6 h, 12 h
Result: Reduced cell viability in COV434 cells with 10 mM treatment after 6 h and 12 h.

Cell Cycle Analysis

Cell Line: rat ovarian granulosa cells
Concentration: 20; 40; 60 mM
Incubation Time: 24 h
Result: Induced G0/G1 phase cell cycle arrest.
Increased the proportion of cells in G0/G1
phase.
Decreased the proportion of cells in S
phase.

Real Time qPCR

Cell Line: rat ovarian granulosa cells
Concentration: 20; 40; 60 mM
Incubation Time: 24 h
Result: Altered expression of cell cycle-related genes p21, Cdk2, and Ccnd1.

Western Blot Analysis

Cell Line: rat ovarian granulosa cells
Concentration: 20; 40; 60 mM
Incubation Time: 24 h
Result: Decreasing Bcl-2 and increased Bax, Caspase3, and Caspase9 levels.
体内研究
(In Vivo)

Hexane-2,5-dione (2.5-3.5 mmol/kg/天;腹腔注射;每周 5 天;持续 17-38 天) 可在成年雄性 Wistar 大鼠中诱发严重神经毒性和睾丸损伤。
Hexane-2,5-dione (2-6 mmol/kg/天;经饮水口服;3-5 周) 可通过破坏支持细胞微管功能、减少生精小管液生成、诱导生殖细胞凋亡及改变干细胞因子亚型表达,在大鼠中引发不可逆的睾丸萎缩,且病情严重程度与给药速率相关。
Hexane-2,5-dione (250-500 mg/kg;灌胃;单次给药,每日 1 次,持续 15-21 天) 可对雄性 LAC Porton 大鼠的脑葡萄糖利用产生剂量依赖性抑制,且高剂量慢性给药会诱发明显的六碳化合物神经病变。

Animal Model: Wistar rats (adult male, 400-500 g, with neurotoxicity)
Dosage: 3.5 mmol/kg/day (17-day treatment); 2.5 mmol/kg/day (38-day treatment)
Administration: i.p.; 5 days/week; 17 days; 38 days
Result: Caused 27% body weight loss.
Exhibited a mean neuropathy score of 5, corresponding to moderate to marked hindlimb paralysis.
Induced numerous neurofilament-packed axonal swellings and scattered axonal degeneration in thoracic and lumbar spinal cord anterior fasciculi.
Caused testicular damage including giant cell formation, spermatogenesis arrest, and pyknotic changes in Sertoli and germinal cell nuclei.
Reached pyrrole adduct concentrations of 7.5 nmol/mg protein in serum, 3.7 nmol/mg protein in brain stem axonal cytoskeletal protein, and 4.7 nmol/mg protein in spinal cord axonal cytoskeletal protein for the 3.5 mmol/kg/day, 17-day group.
Reached pyrrole adduct concentrations of 3.1 nmol/mg protein in serum, 1.7 nmol/mg protein in brain stem axonal cytoskeletal protein, and 2.2 nmol/mg protein in spinal cord axonal cytoskeletal protein for the 2.5 mmol/kg/day, 38-day group.
Showed covalent crosslinking of axonal cytoskeletal protein of 6.4% in brain stem and 12.2% in spinal cord for the 3.5 mmol/kg/day, 17-day group.
Showed covalent crosslinking of axonal cytoskeletal protein of 9.9% in brain stem and 11.6% in spinal cord for the 2.5 mmol/kg/day, 38-day group.
Animal Model: Sprague-Dawley rats
Dosage: 2-6 mmol/kg/day
Administration: oral via drinking water; 3-5 weeks
Result: Altered assembly of purified testis tubulin starting 2 weeks after exposure.
Decreased seminiferous tubule fluid formation by 3 weeks.
Induced large, basally located Sertoli cell vacuoles in stages I, XII, XIII, and XIV as the first histopathological signs of injury, followed by sloughing and loss of germ cells by 4-5 weeks.
Altered the cycle of the seminiferous epithelium, with decreased prevalence of certain stages and increased prevalence of others.
Rendered seminiferous tubules devoid of differentiating germ cells but containing proliferating spermatogonia by 8-12 weeks after a 3-5 week exposure, with this atrophic state persisting for greater than 70 weeks post-exposure.
Caused progressively more severe histopathological alterations in the testis with higher dose-rates, which positively correlated with the extent of microtubule assembly abnormality in purified testicular tubulin.
Induced germ cell death via apoptosis, with DNA fragmentation ladders most prominent 5 weeks into exposure, and increased germ cell apoptosis detected as early as 2 weeks into treatment.
Altered the ratio of soluble stem cell factor (sSCF) to membrane-bound stem cell factor (mSCF) in the testis, which correlated temporally with the onset of atrophy.
Resulted in only 1% seminiferous tubule repopulation after 23 days of exposure, compared to greater than 90% repopulation in rats given depot GnRH agonist therapy for 10 weeks immediately post-exposure.
Animal Model: LAC Porton rats (male, 7-9 weeks of age at end of experimental periods)
Dosage: 250; 500 mg/kg/day
Administration: i.g.; single dose (acute); daily for 15 days (high chronic); daily for 21 days (low chronic)
Result: Caused significant region-dependent decreases in cerebral glucose utilization in high-acute-dose group, with cortical regions, inferior colliculus, and hippocampus most affected, and decreased regional unidirectional glucose flux and permeability-surface area product for glucose influx relative to controls, with no significant changes in regional cerebral blood flow.
Caused significant region-dependent decreases in cerebral glucose utilization in high-chronic-dose group, with inferior colliculus most affected, and significant increases in PS_in in thalamus, hypothalamus, and medulla-pons, with significant region-dependent increases in cerebral blood flow in thalamus, postcingulate cortex, and auditory cortex, and increased regional brain glucose contents relative to controls.
Showed no significant changes in cerebral glucose utilization in low-chronic-dose group, but caused significant region-dependent changes in J_in and PS_in in substantia nigra, auditory cortex, superior colliculus, cerebellum, and medulla-pons.
性状 液体(密度:1.00910 g/cm³)
颜色 Colorless to light yellow

化学信息

分子量 114.14
分子式 C6H10O2
CAS No. 110-13-4
别名 2,5-HD

储存&溶解度

储存方式

Store at room temperature 3 years

In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 200 mg/mL (1752.23 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM8.7612 mL43.8059 mL87.6117 mL219.0293 mL
5 mM1.7522 mL8.7612 mL17.5223 mL43.8059 mL
10 mM0.8761 mL4.3806 mL8.7612 mL21.9029 mL
15 mM0.5841 mL2.9204 mL5.8408 mL14.6020 mL
20 mM0.4381 mL2.1903 mL4.3806 mL10.9515 mL
25 mM0.3504 mL1.7522 mL3.5045 mL8.7612 mL
30 mM0.2920 mL1.4602 mL2.9204 mL7.3010 mL
40 mM0.2190 mL1.0951 mL2.1903 mL5.4757 mL
50 mM0.1752 mL0.8761 mL1.7522 mL4.3806 mL
60 mM0.1460 mL0.7301 mL1.4602 mL3.6505 mL
80 mM0.1095 mL0.5476 mL1.0951 mL2.7379 mL
100 mM0.0876 mL0.4381 mL0.8761 mL2.1903 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用,-20°C储存时,请在6个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础